Arthrosurface(R) HemiCAP(R) Toe Resurfacing Implant Receives Reimbursement Approval From Major Insurance Carriers
FRANKLIN, Mass., Sept. 25 /PRNewswire/ — Arthrosurface, Inc. (http://www.arthrosurface.com/), the developer of less-invasive joint resurfacing systems, announced that its HemiCAP(R) toe hemiarthroplasty product is now approved for reimbursement by Aetna and other major insurance carriers.
“We are very pleased that Aetna has responded to surgeon and patient requests, as well as our own appeal submission, to review and update their coverage policy for these patients that have been facing difficult treatment decisions. We will continue to review coverage policy with several other insurance carriers that have referenced Aetna’s previous position in their own coverage policy statements,” commented Steven Ek, COO.
Metatarsal head resurfacing with the HemiCAP(R) implant provides a modern treatment approach for patients with Grade II and early Grade III MTP changes. This intermediate patient population can be served with a motion-preserving surgical alternative for providing pain relief and functional improvement.
The metatarsal phalangeal joint or great toe is considered one of the most common osteoarthritic joints and the often painful condition of hallux rigidus is reported to be present in females at a rate of 2:1 over males. The underlying disease process of hallux rigidus is not fully understood but it is believed to be associated with joint impingement diseases and previous traumas such as sports or occupational injuries.
Arthrosurface is a medical device manufacturer specializing in the development of cartilage resurfacing systems targeted for the middle aged and active patient. The company’s systems are indicated and FDA cleared for use in the knee, shoulder, hip and toe.
CONTACT: Anthony C. Moretti, CFO of Arthrosurface, Inc.,+1-508-520-3003
Web site: http://arthrosurface.com/